ALL OUR ARTICLES ON COVID-19 AND EMERGING DISEASES

PREVENTION TREATMENTS LIVING WITH EPIDEMIOLOGY HEPATITIS AND HEALTH DRUGS AND
HIV STIS ECONOMICS RDRS

March 23, 2023

The revival of vaccine research: TO CONTINUE

READING
from one pandemic to another April 18, 2023
Ebola: from an animal
The session "The challenges of vaccination: overview" of the ANRS MIE 2023 scientific days
reservoir to a human
was an opportunity for the speakers to discuss this cross-cutting research topic. reservoir

By Gilles Pialoux , vih.org, Charles Roncier , vih.org

April 18, 2023
CD40 COVID-19 COVID-19 AND EMERGING DISEASES HPV NIPAH PROPHYLACTIC VACCINE
Olympic Games 2024: a
VACCINATION risk factor for epidemics

April 14, 2023

The Covid health crisis required enormous acceleration and international mobilization
Zika, “One Health”
around the issue of vaccination. Advances in vaccination have enabled the rapid approach model and
development of effective vaccines, then their availability in an accelerated procedure, within emerging risk in
an extremely tight schedule, to the world population. These advances inform us and shape mainland France
new ways of thinking about vaccine development for other emerging diseases.
April 14, 2023
Professor Adrian Hill (Director of the Jenner Institute, University of Oxford, Oxford, UK) is
Call for applications
part of the world-renowned team that developed the Covid vaccine ChAdOx19, later 2023 for Arbo-France –
marketed by AstraZeneca. His presentation focused on vaccine development strategy, ANRS thesis grants
particularly in the context of epidemic preparedness and response. The Jenner Institute and
AstraZeneca developed the vaccine in unprecedented time, thanks to experience on the
adenovirus vaccine platform used against MERS-CoV (Middle East Respiratory Syndrome
Coronavirus) and research capabilities acquired upstream by the institute. For Adrian Hill,
the key element for the transition to clinical phases and large-scale production was the
IN THE SAME
establishment of partnerships with manufacturers.
CATEGORY -
Adrian Hill (not to be confused with HIV and hepatitis pharmacoepidemiologist Andrew Hill)
offers a model for vaccine development by academic research institutions, envisioning PREVENTION
institution-driven preclinical and early clinical studies and partnerships pre-established with
industrial players specialized in large-scale production for the downstream clinical phases April 26, 2023
and then for distribution. Finally, Adrian Hill presented a promising protein vaccine Breastfeeding and HIV:
candidate against malaria, since it showed an efficacy of more than 75% in children aged 5- Associations await the
17 months in a phase IIb clinical trial. For Adrian Hill,the Covid offered us a full-scale trial. evolution of French
recommendations
Today, we are much more comfortable than before. New technologies continue to appear.
Vaccine technologies are changing very, very quickly . We know how to manufacture
vaccines on a large scale .” The field is in full expansion, but it requires a substantial April 26, 2023
investment from the states: “ We have big military defences, we have to spend as much on Injectable PrEP in
biodefense. » resource-limited
settings, promises and
challenges
From HIV to HPV, including Nipah
Then, in the second presentation, Pr. Yves Lévy ( Inserm , Vaccine Research Institute, April 18, 2023
Créteil) returned to the latest encouraging results of the ANRS VRI06 trial in phase 1. These Olympic Games 2024: a
risk factor for epidemics
revealed that the vaccine candidate CD40.HIVRI .Env was well tolerated and there was a
strong immune response .
April 14, 2023
The Vaccine Research Institute (VRI) was created by the ANRS and the University of Paris- AT-PrEP: a new app to
Est Créteil (UPEC) with the aim of implementing new vaccine strategies against HIV/AIDS make life easier for
and emerging infectious diseases. Yves Lévy therefore presented the platform based on an people taking PrEP
antigen presentation model specifically targeting CD40 on the surface of dendritic cells
(used in VRI06) and how other candidate vaccines are currently being developed, with this
same approach, by LinKinVax, a spin-up according to Yves Lévy's expression from the VRI.
That is to say a structure between spin-off and start-up, independent, but funded by
investors to scale up beyond Phase I trials. This vaccine platform developed by LinKinvax is
supported by the ANRS-MIE, Inserm and many laboratories or investors.

To understand the hope it arouses, we have to go back to the 2011 Nobel Prize in Medicine,
which revolutionized the immunological approach by deciphering what is called adaptive
immunity, the first lines of which involve cells dendritic. Marauding the blood, skin and
other tissues, dendritic cells play the role of sentinels, on the lookout for any foreign agent.
As soon as one presents itself, they detect it thanks to specific receptors then ingest it by
phagocytosis, before digesting it and presenting its antigens on their surface. After
migrating to the ganglia, the dendritic cells trigger the activation of adaptive immunity cells,
including T and B lymphocytes, which learn to recognize antigen and target their attacks. As
Yves Levy summarizes:“By allowing precise targeting of a dendritic cell with the right
antigen, our solution paves the way for the development of a wide range of new vaccines,
both preventive and therapeutic .”

RefiningtheDC-targetingvaccinationfor *frontiersFrontiersinImmunology
preventingemerginginfectiousdiseasesYadiraPastor",NourGhazzaui",AdeleHammoudi
DOI10.3389/fimmu.2022949779 2022 MireilleCentlivre',SylvainCardinaud'andYvesLevy124

Lietal.JExpMed,2012
FlamarALJImmunol2012
FlamarALAIDS2013
EpaulardOJImmunol2014
LevyYEurJImmunol2014
FlamarALPLoSOne2015
ZurawskiGPLoSOne,2016
SalabertN,EurJImmunol2016
ZurawskiG,JVirol,2017
FlamarALJPIOSOne2018
ChengL,JCI,2018
Thiebaut,FontImmunol,2019
Chengetal.Vaccine2017

CORDCONS
FlamarAL.PLoSOne2018
GodotV.PLoSPath2020
CegliaVJImmunol2021
ChengL.FImmunol2021
Bytargetingviralantigentodendriticcells, CegliaV,FImmunol2022
ColeonSetal.Ebiomed2022
weaimtofavorantigenpresentationand MarlinRetal.NatCom2022
activationofantigen-specificcellular PastorYetal.FrontImm2022

andhumoralimmuneresponses VACCINE
RESEARCH
INSTITUTE

Targeting dendritic cells in vaccine research. Y. Lévy, ANRS-MIE 2023.

LinKinvax's vaccine platform is a fully humanized, easy-to-produce monoclonal antibody

that targets dendritic cells to elicit an adaptive immune response. On the other hand, the
modulation of the associated antigens allows it to be easily adapted to target specific
pathogens. Thus, this platform, like messenger RNA or adenovirus vector vaccines, can
attack several diseases and infectious agents: HPV 16 (responsible for 80% of HPV-induced
ENT cancers), HIV, SARS-Cov- 2, Tuberculosis, Nipah (a zoonosis which sometimes causes
epidemic outbreaks in India in particular, with a fatality rate between 40% and 75%),
Chlamydia, etc.

Adaptation of the VRI CD40 targeting platform to (re)emerging infectious diseases. Y.Lévy, ANRS-MIE 2023.

For the time being, several Phase 1 trials are underway or in preparation: two against HIV —
one preventive and one therapeutic—, one against cancer linked to HP 16 papillomavirus
and another to fight against SARS-CoV-2. .

Regarding HIV vaccine trials, Yves Levy, who was in charge of vaccine research at the ANRS,
knows how much it is the Phase III trials that decide the future. Be that as it may, this
effervescence of vaccine platforms is good news in itself.

Christophe Martet, new president of Vers Paris sans

Sidaction 2023: A survey on information and prevention
sida: “We support concrete projects, without replacing
among young people
associations in the field”

hiv.org Our partners They support us

Contact Ministry of Health and Prevention ➚ AAZ ➚
Who are we ? ➚ Aids ➚ AbbVie ➚
Credits ➚ ANRS ➚ Gilead ➚
Legal Notice ➚ Crips Ile-de-France ➚ GSK ➚
FAQs ➚ Individual ➚
CeGIDD map ➚ Janssen ➚
Our Brochure ➚ MSD ➚
Our posters ➚ Pfizer ➚
Swaps in English ➚ Viatris ➚
Glossary ➚ ViiV Healthcare ➚
RSS ➚
 ALL OUR ARTICLES ON COVID-19 AND EMERGING DISEASES

PREVENTION TREATMENTS LIVING WITH EPIDEMIOLOGY HEPATITIS AND HEALTH DRUGS AND
HIV STIS ECONOMICS RDRS

April 20, 2023

Removal of the AME: the concern TO CONTINUE

READING
of associations and health February 17, 2023

professionals Confinement and excess

mortality among
immigrants: the
“syndemic pandemic”
Faced with the amendment passed in the Senate abolishing State Medical Aid (AME) and
leaving only the payment of urgent care, several learned societies and France assos santé
are alarmed by the consequences in terms of access to care for foreigners in an irregular October 19, 2022
situation, but also public health. Impact of COVID on liver
diseases and STIs
By Charles Roncier , hiv.org

HEALTH CARE ACCESS SOUL SENATE October 9, 2022

Impact of COVID on the
management and
The State Medical Aid (AME), set up in 2000, allows foreigners in an irregular situation to elimination of Hepatitis
C
benefit from reimbursement of their care. On March 15, 2023, an amendment proposing its
deletion was voted on in the Senate. Several learned societies, including the Society of
Infectious Pathologies (SPILF), the French-speaking Resuscitation Society (SRLF), and the October 4, 2021
French Society of Emergency Medicine (SFMU), as well as France assos santé , are In Grenoble, a call to see
concerned about the consequences for access to care for this already highly exposed the end of AIDS
population 1 . According to these organizations, the amendment goes against the principles
of human rights guaranteeing the right to health for all.

IN THE SAME
CATEGORY -
HEALTH
ECONOMICS

April 14, 2023

Call for applications
2023 for Arbo-France –
ANRS thesis grants

March 24, 2023

Sidaction 2023: A survey
The amendment on the Senate website on information and
prevention among
Même en ne considérant que l’angle de la santé publique, cette suppression constitue un young people
non-sens économique et pourrait avoir de graves conséquences pour le système de santé
français : les pathologies hospitalières prises en charge tardivement sont particulièrement
March 7, 2023
coûteuses. La migration pour raison de santé, souvent invoquée pour attaquer l’AME, est
Christophe Martet, new
pourtant minoritaire parmi les motifs de départ des pays d’origine et les études constatent à president of Vers Paris
l’inverse un non-recours à ce droit important (49% selon l’enquête Premiers pas, y compris sans sida: “We support
pour les personnes atteintes de maladies chroniques). concrete projects,
without replacing
Un coût extrêmement faible associations in the field”

Les organisations signataires rappellent que le coût des soins couverts par l’AME ne
February 17, 2023
représente que 0,4% des dépenses de l’Assurance maladie en France 2 et que plusieurs Confinement and excess
économistes de la santé n’ont pas constaté de surconsommation de soins inutiles par les mortality among
bénéficiaires. immigrants: the
“syndemic pandemic”
Les sociétés savantes appellent les députés et les sénateurs à ne pas supprimer l’AME et à
revenir sur les restrictions qui lui ont été adjointes. France assos santé dénonce également
les restrictions apportées en commission des lois du Sénat et appelle à un accès effectif aux
soins pour les étrangers en situation irrégulière. D’autres organisations ont dénoncé cette
suppression, comme la Coordination nationale des comités de défense des hôpitaux et
maternités de proximité, qui a déclaré dans un communiqué: «À une époque où la
pandémie a démontré la nécessité de penser la santé comme un bien de l’humanité à
défendre ensemble, ces reculs ne sont pas des réponses de santé, mais des outils de
ségrégation pour entretenir et flatter les peurs de l’autre.»

The integration of the AME into the general social security system, as requested for a long
time by humanitarian associations and many health actors, appears to be the only solution
to put an end to these regular threats against access to care. for everyone.

Injectable PrEP in resource-limited settings, promises

Ebola: from an animal reservoir to a human reservoir
and challenges

hiv.org Our partners They support us

Contact Ministry of Health and Prevention ➚ AAZ ➚
Who are we ? ➚ Aids ➚ AbbVie ➚
Credits ➚ ANRS ➚ Gilead ➚
Legal Notice ➚ Crips Ile-de-France ➚ GSK ➚
FAQs ➚ Individual ➚
CeGIDD map ➚ Janssen ➚
Our Brochure ➚ MSD ➚
Our posters ➚ Pfizer ➚
Swaps in English ➚ Viatris ➚
Glossary ➚ ViiV Healthcare ➚
RSS ➚
 ALL OUR ARTICLES ON COVID-19 AND EMERGING DISEASES

PREVENTION TREATMENTS LIVING WITH EPIDEMIOLOGY HEPATITIS AND HEALTH DRUGS AND
HIV STIS ECONOMICS RDRS

April 26, 2023

Breastfeeding and HIV: TO CONTINUE

READING
Associations await the evolution February 15, 2022

of French recommendations Children exposed to HIV

in utero, but not
infected: evidence for
action
Overseas, new guidelines support shared decision-making regarding infant feeding by
women living with HIV. French associations are calling for a similar change in national
recommendations, which advise against breastfeeding for the time being. January 30, 2020
UNODC: report on the
By Charles Roncier , hiv.org planet of drugs

FEEDING WITH MILK PMTCT EXPERT REPORT RECOMMENDATIONS

November 26, 2019
PrEP: new indicators to
If, in France and in most countries of the North, breastfeeding remains not recommended recommend more widely
for HIV-positive women, some countries are beginning to adopt a more flexible position.
Thus, Switzerland has changed its recommendations in this area (end of 2018) and, in the
July 25, 2019
case of an "optimal scenario" in terms of treatment (effective and suppressing the viral load), Data on the use of
proposes that the decision to breastfeed or not be taken in consultation with the mother. dolutegravir in women
The recent American recommendations, updated in January 2023 and presented at the of childbearing
CROI of the same year, also show a development in the same direction, now supporting potential
shared decision-making with health professionals.

TasP effect and breastfeeding

In these two countries, it is the taking into account of scientific advances, in particular the IN THE SAME
TaSP revolution, which confirms the absence of HIV transmission , at least by sexual means
among people on effective antiretroviral (ARV) treatment, which led to the evolution of CATEGORY -
these recommendations. And this, even if the data concerning the transmission of HIV by PREVENTION
breastfeeding are less numerous and that the threshold of viral load which would make it
possible to avoid transmission of HIV via breastfeeding is not known.
April 26, 2023
Presented in 2021, the DolPHIN-2 trial demonstrated that the risk of HIV transmission Injectable PrEP in
through breastfeeding was low when the mother was on effective ARV treatment. Of 242 resource-limited
settings, promises and
children born to HIV-positive women in Uganda and South Africa and exclusively breastfed challenges
for six months, only one baby had contracted the virus. Transmission is therefore rare and
appears to occur in less than 1% of cases.
April 18, 2023
Olympic Games 2024: a
French associations mobilized risk factor for epidemics

In France, about 1,500 women living with HIV give birth each year, and the update of the
chapter "Procreation and HIV: desire for children, contraception, care of pregnant women April 14, 2023
and newborns" of the report experts, the Delobel report, is long overdue. It should AT-PrEP: a new app to
nevertheless be validated during the first quarter of 2023 by the High Authority for Health make life easier for
people taking PrEP
(HAS).

In a joint forum published on April 21, 2023 , French associations, including AIDES, TRT-5 March 23, 2023
CHV, the Family Committee, Sidaction and Family Planning, welcome these advances The revival of vaccine
abroad and hope that the new French recommendations take into account the latest research: from one
scientific data. pandemic to another

The associations also support the need for support for "all breastfeeding people living with
HIV" (cis women, transgender men and non-binary people) and their involvement in all
decisions relating to their pregnancy and feeding with milk. They also recall that stigma and
discrimination against people living with HIV can be major obstacles to the implementation
of more flexible and individualized recommendations.

“People's participation in the decisions that concern them makes it possible to improve
compliance with treatments and to individualize therapeutic decisions” , believe the
associations.

The signatories therefore call for increased awareness of the general public, health
professionals and political authorities on the issue of breastfeeding and HIV, in order to
guarantee better support for the women concerned.

Injectable PrEP in resource-limited settings, promises

and challenges

hiv.org Our partners They support us

Contact Ministry of Health and Prevention ➚ AAZ ➚
Who are we ? ➚ Aids ➚ AbbVie ➚
Credits ➚ ANRS ➚ Gilead ➚
Legal Notice ➚ Crips Ile-de-France ➚ GSK ➚
FAQs ➚ Individual ➚
CeGIDD map ➚ Janssen ➚
Our Brochure ➚ MSD ➚
Our posters ➚ Pfizer ➚
Swaps in English ➚ Viatris ➚
Glossary ➚ ViiV Healthcare ➚
RSS ➚